Crohn’s & Colitis Australia welcomes the Federal Government’s announcement that SIMPONI® (golimumab) will be listed on the Pharmaceutical Benefits Scheme (PBS) for people living with moderate to severe ulcerative colitis.
“It is vital that people affected by ulcerative colitis have access to affordable treatment options to help them live well. The debilitating symptoms of the condition —loss of appetite and weight loss, pain, fatigue and diarrhoea —can be devastating for people diagnosed with colitis, often impacting their mental health as well. The new PBS listing will be incredibly welcome news for the many Australians living with this life-long condition,” said CCA CEO Associate Professor Leanne Raven.
SIMPONI is an anti-tumour necrosis factor (TNF) alpha treatment delivered through under-the-skin injection monthly. The therapy is effective and offers patients a convenient option for a self-administered anti-TNF, especially helpful for those who have to travel a long distance to receive infusions.
If you have been diagnosed with or are living with moderate or ulcerative colitis, please speak to your doctor about the treatment.